Belite Bio, Inc. ADR (BLTE) Price & Analysis

Compare

41 Followers

BLTE Stock Chart & Stats

$90.37

-$1.45(-2.47%)

At close: Jan 08 4:00 PM EST

$90.37

-$1.45(-2.47%)

Day’s Range― - ―

52-Week Range$49.00 - $91.92

Previous CloseN/A

Volume15.47K

Average Volume (3M)64.23K

Market Cap

$2.86B

Enterprise Value$1.73B

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Nov 18, 2025

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding32,833,400

10 Day Avg. Volume75,810

30 Day Avg. Volume64,229

Financial Highlights & Ratios

PEG Ratio63.44

Price to Book (P/B)13.21

Price to Sales (P/S)0.00

P/FCF Ratio-65.58

Enterprise Value/Market Cap0.61

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-32.66

Forecast

1Y Price Target

$93.25

Price Target Upside3.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial PositionSuccessful completion of recent equity financing has strengthened the company's financial position, potentially supporting future commercial launch.

Regulatory ApprovalThe National Medical Products Administration of China has agreed to accept the New Drug Application with priority review for tinlarebant for the treatment of Stargardt disease.

Regulatory DesignationsTinlarebant has been granted several designations in the U.S., including Breakthrough Therapy and Orphan Drug, which are favorable for regulatory approval.

Bears Say

Regulatory Approval ChallengesDespite unorthodox developments, there is belief that the most likely outcome is positive data and approval from various regulators.

Belite Bio, Inc. ADR News

Leerink bullish on Belite Bio, says tinlarebant news another positive data point

Leerink analyst Marc Goodman notes Belite Bio (BLTE) announced China’s NMPA has accepted the NDA for tinlarebant in...

6d ago

BLTE

Belite Bio announces China’s NMPA agreed to accept NDA for Tinlarebant

Belite Bio (BLTE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, NMPA, has...

6d ago

BLTE

Belite Bio price target lowered to $98 from $100 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Belite Bio (BLTE) to $98 from $100 and keeps a...

1M ago

BLTE

Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position

Belite Bio, Inc. ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael...

1M ago

BLTE

Belite Bio completes Phase 3 DRAGON trial of Tinlarebant

Belite Bio (BLTE) announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial...

1M ago

BLTE

Belite Bio announces up to $250M upsized private placement financing

Belite Bio (BLTE) entered into securities purchase agreements with leading healthcare investors for a private placement in public...

1M ago

BLTE

Belite Bio Secures $125 Million in PIPE Financing with Potential for More

An update from Belite Bio, Inc. ADR ( ($BLTE) ) is now available. On September 8, 2025, Belite...

1M ago

BLTE

Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio

In a report released on August 11, Marc Goodman from Leerink Partners maintained a Buy rating on Belite...

2M ago

BLTE

Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease

Belite Bio, Inc. ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael...

2M ago

BLTE

Belite Bio’s Earnings Call: Progress Amid Challenges

Belite Bio, Inc. ADR (($BLTE)) has held its Q2 earnings call. Read on for the main highlights of...

2M ago

BLTE

Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc.

Belite Bio, Inc. ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi...

2M ago

BLTE

Belite Bio Advances Retinal Disease Treatments Amid Financial Growth

Belite Bio, Inc. ADR ( ($BLTE) ) has released its Q2 earnings. Here is a breakdown of the...

2M ago

BLTE

Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones

Belite Bio, Inc. ADR ( ($BLTE) ) just unveiled an update. On August 11, 2025, Belite Bio announced...

2M ago

BLTE

Belite Bio reports Q2 EPS (50c), consensus (42c)

As of June 30 the Company had $149.2M in cash, liquidity funds, time deposits, and U.S treasury bills....

2M ago

BLTE

BLTE FAQ

What was Belite Bio, Inc. ADR’s price range in the past 12 months?

Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $91.92 in the past 12 months.

What is Belite Bio, Inc. ADR’s market cap?

Belite Bio, Inc. ADR’s market cap is $2.86B.

When is Belite Bio, Inc. ADR’s upcoming earnings report date?

Belite Bio, Inc. ADR’s upcoming earnings report date is Nov 18, 2025 which is in 28 days.

How were Belite Bio, Inc. ADR’s earnings last quarter?

Belite Bio, Inc. ADR released its earnings results on Aug 11, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.09.

Is Belite Bio, Inc. ADR overvalued?

According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Belite Bio, Inc. ADR pay dividends?

Belite Bio, Inc. ADR does not currently pay dividends.

What is Belite Bio, Inc. ADR’s EPS estimate?

Belite Bio, Inc. ADR’s EPS estimate is -0.49.

How many shares outstanding does Belite Bio, Inc. ADR have?

Belite Bio, Inc. ADR has 32,833,400 shares outstanding.

What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?

Belite Bio, Inc. ADR reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went down -0.544%.

Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?

Currently, no hedge funds are holding shares in BLTE

Belite Bio, Inc. ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.34%

Trailing 12-Months

Asset Growth

32.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Belite Bio, Inc. ADR

Belite Bio, Inc. ADR (BLTE) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics to address significant unmet medical needs in the fields of ophthalmology and metabolic diseases. The company is engaged in developing innovative treatments aimed at improving patient outcomes, particularly in the areas of retinal degenerative diseases such as Stargardt disease and dry age-related macular degeneration.

Belite Bio, Inc. ADR (BLTE) Earnings & Revenues

Historic Earnings Reports

BLTE Company Deck

BLTE Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights significant regulatory and clinical progress for Tinlarebant, indicating a strong position in advancing treatments for Stargardt disease and geographic atrophy. However, financial losses and the potential for extended regulatory timelines pose challenges.View all BLTE earnings summaries

BLTE Stock 12 Month Forecast

Average Price Target

$93.25

▲(3.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","63":"$63","79":"$79","95":"$95","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,63,79,95,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.5,76.3076923076923,79.11538461538461,81.92307692307692,84.73076923076923,87.53846153846153,90.34615384615384,93.15384615384616,95.96153846153845,98.76923076923077,101.57692307692307,104.38461538461539,107.1923076923077,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.5,75.01923076923077,76.53846153846153,78.0576923076923,79.57692307692308,81.09615384615384,82.61538461538461,84.13461538461539,85.65384615384616,87.17307692307692,88.6923076923077,90.21153846153845,91.73076923076923,{"y":93.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.5,74,74.5,75,75.5,76,76.5,77,77.5,78,78.5,79,79.5,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.95,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >